RETRACTED: Study on Attenuating Angiogenesis and Epithelial–Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2

Jiang, Si‐Cong; Liu, Xi; Li, Daojing; Yan, Mei; Cheng, Ju; Sun, Jun; Jiang, Feng

doi:10.1177/1533033818797587

Cited by 6 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further IHC analyses in clinically invasive and metastatic HCC samples also suggested that MAGEC2 promoted HCC invasion and metastasis via EMT. Similarly, Jiang et al25 recently reported that MAGEC2 upregulated the expression of EMT-related proteins and enhanced growth and metastasis in NSCLC; Chen et al29 stated that MAGEC2 facilitated colony formation and migration by inducing the EMT of tumour cells in oesophageal squamous cell carcinoma; Yang et al30 described that MAGEC2 acted as an EMT inducer and was dramatically associated with breast cancer metastasis. Our present results are consistent with previous studies on the EMT-promoting role of MAGEC2 in human cancers.…”

Section: Discussionmentioning

confidence: 90%

“…Ki67 expression in nude mice was examined, and the results demonstrated that Ki67 expression was significantly reduced after MAGEC2 knockdown, which further implied the facilitating role of MAGEC2 in tumour growth. Similarly, Bhatia et al23 showed that MAGEC2 promoted tumour growth and tumourigenicity in melanoma; Hao et al24 revealed that MAGEC2 overexpression increased the G1-S transition and cell proliferation in multiple kinds of cancer, including colorectal cancer, cervical cancer, breast cancer and melanoma; Jiang et al25 stated that MAGEC2 promoted proliferation, migration, and invasion and suppressed apoptosis in non-small cell lung carcinoma (NSCLC) cell lines, and MAGEC2 could also facilitate tumour growth and metastasis in NSCLC xenografts.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition

Yuan

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

PurposeAlthough MAGEC2 was first cloned from a human hepatocellular carcinoma (HCC) cDNA library by serum screening, the detailed attributes of MAGEC2 in HCC have rarely been elucidated.Patients and methodsIn this study, The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were consulted to analyse the expression of MAGEC2 mRNA in liver cancer. Immunohistochemistry (IHC) analysis was performed to detect MAGEC2 expression in HCC, and the relationship between MAGEC2 expression and the clinicopathological characteristics of HCC patients was evaluated. Then, we employed the short hairpin (sh)RNA-mediated knockdown of MAGEC2 in HCC cell lines to explore the function of MAGEC2 in HCC development. Finally, the expression of epithelial-mesenchymal transition (EMT) markers in HCC xenografts and clinical samples was investigated.ResultsThe results showed a remarkably higher level of MAGEC2 expression in HCC tissues than in noncancerous tissues, and MAGEC2 expression could be used as an independent prognostic factor for overall survival in HCC. Moreover, sh-MAGEC2 inhibited a series of HCC malignant behaviours both in vitro and in vivo. Finally, decreased MAGEC2 expression and low levels of EMT markers were detected in sh-MAGEC2 xenografts, while increased MAGEC2 expression and high levels of EMT markers were observed in invasive and metastatic HCC samples.ConclusionTaken together, our data imply that MAGEC2 is a novel prognostic marker for HCC and that MAGEC2 significantly promotes HCC tumourigenesis by inducing EMT. Targeting MAGEC2 may provide a promising therapeutic strategy for HCC treatment.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 97%

MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition

Yuan

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…SSX2 interacts with Rab3IP to promote EMT [22]. MAGEC2, which is highly expressed in non-small cell lung cancer cells, promotes angiogenesis and EMT [23]. MAGE-A3 shows high expression in cervical cancer cells and promotes cancer cell metastasis by activating Wingless-related integration site (Wnt) signaling [24].…”

Section: Of 26mentioning

confidence: 99%

Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy

Shim,

Jo,

Jeoung

2023

IJMS

View full text Add to dashboard Cite

In the last few decades, RNA-based drugs have emerged as a promising candidate in the treatment of various diseases. The introduction of messenger RNA (mRNA) as a vaccine or therapeutic agent enables the production of almost any functional protein/peptide. The key to applying RNA therapy in clinical trials is developing safe and effective delivery systems. Exosomes and lipid nanoparticles (LNPs) have been exploited as promising vehicles for drug delivery. This review discusses the feasibility of exosomes and LNPs as vehicles for mRNA delivery. Cancer/testis antigens (CTAs) show restricted expression in normal tissues and widespread expression in cancer tissues. Many of these CTAs show expression in the sera of patients with cancers. These characteristics of CTAs make them excellent targets for cancer immunotherapy. This review summarizes the roles of CTAs in various life processes and current studies on mRNAs encoding CTAs. Clinical studies present the beneficial effects of mRNAs encoding CTAs in patients with cancers. This review highlight clinical studies employing mRNA-LNPs encoding CTAs.

show abstract

“…Epithelial-mesenchymal transition (EMT) and angiogenesis are two critical components that support tumor growth and metastasis in the tumor microenvironment ( Jiang et al, 2018 ). EMT, a process in which epithelial cells transform phenotypically into mesenchymal cells, lose their adhesive properties and cell-cell contacts and gain migration properties, has been shown to play an important role in cancer metastasis ( Suda et al, 2017 ; Li et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes

BABAHAN,

ABGARMI,

SONUGÜR

et al. 2023

Turkish Journal of Biology

View full text Add to dashboard Cite

Background/aim The role of PD-L1 in regulating the immunosuppressive tumor microenvironment via its binding on PD-1 receptors is extensively studied. The PD-1/PD-L1 axis is a significant way of cancer immune escape, and PD-L1 expression on tumor cells is suggested as a predictive marker for anti-PD-1/PD-L1 monoclonal antibodies (MoAbs). However, the tumor-intrinsic role of PD-L1 is not known well. Therefore, we aimed to investigate the effects of anti-PD-L1 antibodies on the expression of angiogenesis and metastasis-related genes in tumor cells. Materials and methods The experiments were done with prostate cancer and melanoma cells with low PD-L1 expression (<5%) and prostate and breast cancer cells with high PD-L1 expression (>50%). The gene and protein expressions of VEGFA, E-cadherin, TGFβ1, EGFR, and bFGF in tumor cells were assayed at the 3 different doses of the anti-PD-L1 antibody. Results We found that VEGFA, E-cadherin and TGFβ1 expressions increased in PD-L1 high cells but decreased in PD-L1 low cells after anti-PD-L1 treatment. EGFR expression levels were variable in PD-L1 high cells, while decreased in PD-L1 low cells upon treatment. Also, the anti-PD-L1 antibody was found to increase bFGF expression in the prostate cancer cell line with high PD-L1 expression. Conclusion Our results suggest that the binding of PD-L1 on tumor cells by an anti-PD-L1 monoclonal antibody may affect tumor-intrinsic mechanisms. The activation of angiogenesis and metastasis-related pathways by anti-PD-L1 treatment in PD-L1 high tumors might be a tumor-promoting mechanism. The decrease of VEGFA, TGFβ1 and EGFR upon anti-PD-L1 treatment in PD-L1 low tumor cells provides a rationale for the use of those antibodies in PD-L1 low tumors.

show abstract

RETRACTED: Study on Attenuating Angiogenesis and Epithelial–Mesenchymal Transition (EMT) of Non-Small Cell Lung Carcinoma (NSCLC) by Regulating MAGEC2

Cited by 6 publications

References 34 publications

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

<p>MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition</p>

Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy

The effects of anti-PD-L1 monoclonal antibody on the expression of angiogenesis and invasion-related genes

Contact Info

Product

Resources

About